Bioxcel Therapeutics Inc (BTAI) |
|
56.34 -0.64 (-1.12%)
|
02-25 12:24 |
|
Open: |
57.46 |
Pre. Close: |
56.98 |
|
High:
|
60.36 |
Low:
|
56.1 |
|
Volume:
|
182,619 |
Market Cap:
|
1,373M |
|
|
|
|
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
58.236 - 58.439 |
58.439 - 58.624 |
|
Low:
|
52.998 - 53.245 |
53.245 - 53.471 |
|
Close:
|
56.57 - 56.931 |
56.931 - 57.261 |
|
Technical analysis |
as of: 2021-02-25 11:43:01 AM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 79.12 One year: 92.41 |
| Support: |
Support1: 53.75 Support2: 45.10 |
| Resistance: |
Resistance1: 67.74 Resistance2: 79.12 |
| Pivot: |
57.62  |
| Moving Average: |
MA(5): 55.79 MA(20): 55.73
MA(100): 50.46 MA(250): 44.74 |
| MACD: |
MACD(12,26): 1.34 Signal(9): 1.68  |
| Stochastic oscillator: |
%K(14,3): 37.50 %D(3): 36.59 |
| RSI: |
RSI(14): 55.43 |
| 52-week: |
High: 71.50 Low: 13.77 Change(%): 53.2 |
| Average Vol(K): |
3-Month: 53268 10-Days: 45731 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.BTAI has closed above bottom band by 48.5%. Bollinger Bands are 6.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 25 Feb 2021
BioXcel Therapeutics Starts Testing BXCL501 In Mid-Stage Delirium-Related Agitation Study - Benzinga
Wed, 24 Feb 2021
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) to Post FY2025 Earnings of $14.59 Per Share, Truist Securiti Forecasts - MarketBeat
Wed, 17 Feb 2021
BTAI: BXCL701 Shows Encouraging Anti-Tumor Activity When Combined with Pembrolizumab in mCRPC… - Yahoo Finance
Tue, 16 Feb 2021
Here's Why We're Not Too Worried About BioXcel Therapeutics' (NASDAQ:BTAI) Cash Burn Situation - Yahoo Finance
Tue, 09 Feb 2021
BioXcel Therapeutics - Consensus Indicates Potential 93.9% Upside - DirectorsTalk Interviews
Thu, 04 Feb 2021
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Expected to Post Earnings of -$0.87 Per Share - MarketBeat
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
24 |
| Shares Float (M) |
15 |
|
% Held by Insiders
|
39.80 |
|
% Held by Institutions
|
53.92 |
|
Shares Short (K)
|
3,670 |
|
Shares Short P. Month (K)
|
3,190 |
Stock Financials |
|
EPS
|
-3.450 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
9.070 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-30.3 |
|
Return on Equity (ttm)
|
-54.3 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-2.806 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-54 |
|
Levered Free Cash Flow (M)
|
-28 |
Stock Valuations |
|
PE Ratio
|
-16.65 |
|
PEG Ratio
|
|
|
Price to Book value
|
6.33 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-25.84 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
